REDUCTION IN RATE AND RISK
OF ORGAN DAMAGE PROGRESSION

REDUCTION IN RATE
AND RISK OF ORGAN
DAMAGE PROGRESSION

The impact of BENLYSTA was evaluated in a real-world analysis of organ damage progression.

REDUCTION OF ORGAN DAMAGE PROGRESSION1

Icon: Organ Damage Progression

Reduction of organ damage progression based on mean change in organ damage (SDI) from baseline to Year 5*

Primary endpoint
Graph: BENLYSTA + ST showed a 0.283 Mean Change in SDI Score and ST alone showed 0.717
Graph: BENLYSTA + ST showed a 0.283 Mean Change in SDI Score and ST alone showed 0.717
Real-world, post-hoc, propensity score-matched (PSM) analysis. Results are descriptive. See study design for data limitations.

SDI = SLICC/ACR Damage Index; ST = standard therapy; TLC = Toronto Lupus Cohort.
* Includes all patients with ≥5 years of follow-up.

  • What was the study design?

    Study design1

    A post-hoc, PSM comparative analysis was performed to assess the difference in organ damage (SDI) progression between patients in BLISS-76 LTE* and from the TLC.

    Graph: PSM Analysis between BLISS-76 long-term extension and patients from the TLC
    Graph: PSM Analysis between BLISS-76 long-term extension and patients from the TLC

    KEY LIMITATIONS OF THIS PSM STUDY1

    • Post-hoc analysis
    • Patients matched based on known variables only
    • Patients could not be matched by year of entry into the study
    • Differences in patient populations

    LTE = long-term extension; PSM = propensity score matching; ST = standard therapy; TLC = Toronto Lupus Cohort.

    * To be eligible, patients on BENLYSTA had to be in the United States; regimen was BENLYSTA IV 10 mg/kg + ST.

    † Chosen based on its size, the extent of organ damage in patients, and the severity of disease activity. Regimen was ST alone.

     

  • What patient characteristics were used in the PSM analysis?

    PSM: A method to match and compare patients from different studies1

    Patients are matched based on propensity scores calculated using the 17 predictors of organ damage listed below:

    BLISS Baseline Characteristics

    Once matched, any observed differences between patients are presumed to be a result of the treatment.

    ACR = American College of Rheumatology; PSM = propensity score matching; SDI = SLICC/ACR Damage Index;
    SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index.

REDUCTION IN RATE OF ORGAN DAMAGE PROGRESSION1

Icon: Organ Damage Progression

Annual probability of progression is based on the increase in SDI score per year

Secondary endpoint
Chart: Organ Damage Progression
Chart: Organ Damage Progression

Real-world, post-hoc, propensity score-matched analysis. Results are descriptive. See study design for data limitations.

CI = confidence interval; HR = hazard ratio; SDI = SLICC/ACR Damage Index; ST = standard therapy.

* Based on SDI score increases per year in patients with ≥1 year follow up.

Icon: Progression of Organ Damage

What could slowing the progression of organ damage mean for your patients?